




About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged transactional research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030 Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO[®]) antibody medicines.


Our Strengths & Differentiators

- World-Class antibody biology knowledge and deep insight into disease targets
- Discovery and development engine with proprietary technologies that allow us to build a world-class pipeline
- In-house expertise with solid track record of building successful strategic partnerships
- Pipeline of potential best-in-class and first-in-class therapies
- Experienced, diverse leadership team


How we Operate



Genmab's Growing Organization & Presence



2023 Financials (DKK)



Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics

Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases

Our Values

- Passion for Innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Strong Pipeline of Potential 1st-in-class/Best-in-class Product Candidates

Innovative Pipeline: Genmab's Proprietary¹ Products

Product	Developed By	Target(s)	Technology	Disease Indications	Most Advanced Development Phase			
					Preclinical	1	2	3
Epcoritamab	Co-development Genmab / AbbVie	CD3, CD20	DuoBody	Relapsed/refractory DLBCL	█	█	█	█
				Relapsed/refractory FL	█	█	█	█
				First line DLBCL	█	█	█	█
				First line FL	█	█	█	█
				B-cell NHL	█	█	█	█
				Relapsed/refractory CLL & Richter's Syndrome	█	█	█	█
Aggressive mature B-cell neoplasms in pediatric patients	█	█	█	█				
Tisotumab vedotin	Co-development Genmab / Pfizer	Tissue factor	ADC	Solid tumors	█	█	█	█
Acasunlimab (GEN1046)	Genmab	PD-L1, 4-1BB	DuoBody	NSCLC Solid tumors	█	█	█	█
Rinatabart Sesutecan (Rina-S, PRO1184)	Genmab	FRα	ADC	PROC Solid tumors	█	█	█	█
GEN1042 (BNT312)	Co-development Genmab / BioNTech	CD40, 4-1BB	DuoBody	Solid tumors	█	█	█	█
GEN3014	Genmab ²	CD38	HexaBody	Hematologic malignancies	█	█	█	█
GEN1059 (BNT314)	Co-development Genmab / BioNTech	EpCAM, 4-1BB	DuoBody	Solid tumors	█	█	█	█
GEN1055 (BNT315)	Co-development Genmab / BioNTech	OX40	HexaBody	Solid tumors	█	█	█	█
GEN1160 (PRO1160)	Genmab	CD70	ADC	Advanced solid and liquid tumors	█	█	█	█
GEN1107 (PRO1107)	Genmab	PTK7	ADC	Advanced solid tumors	█	█	█	█
GEN1057	Genmab	FAPα, DR4	DuoBody	Solid tumors	█	█	█	█

For more information about our pipeline, visit www.Genmab.com/pipeline

Approved Medicines Including Genmab's Innovation

Tivdak®, first Genmab owned product on market. Genmab owned, co-developed and co-promoted in partnership with Pfizer

EPKINLY® /TEPKINLY® in partnership with AbbVie, second Genmab owned product on market

DARZALEX®, RYBREVANT®, TECVAYLI® and TALVEY® discovered and/or developed & marketed by Janssen

Kesimpta® developed & marketed by Novartis

TEPEZZA® developed & marketed by Amgen

>40 Cumulative INDs since 1999

Created by Genmab or with Genmab's technologies

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines **DuoBody** and **HexaBody** platforms
- Creates bispecific antibodies with target mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by **HexaBody** platform
- Combines dual targeting with enhanced selectivity & potency

Proprietary ADC Technology

- Inherited Proprietary antibody-drug linker technology from acquisition of ProfoundBio
- Blends innovative and proven methods to design ADCs leading to potentially enhanced therapeutic outcomes

Notes

1 Certain product candidates in development with partners, as noted: Tisotumab vedotin 50:50 partnership with Pfizer; epcoritamab 50:50 partnership with AbbVie; DuoBody-CD40x4 -1BB and GEN1059 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.

2 Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. November 6, 2024